SciBase Holding AB (SCIB) AI Stock Analysis

• Market Cap: kr126.86M
• Dividend Yield: N/A
• Average Volume (3M): 190.74K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.58
• Revenue Growth: 27.78%
• EPS Growth: 43.32%
• Country: SE
• Employees: 32
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Devices
• EPS (TTM): -0.09
• Shares Outstanding: 338,295,620
• 10 Day Avg. Volume: 305,130
• 30 Day Avg. Volume: 190,737
• PEG Ratio: 0.62
• Price to Book (P/B): 10.68
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 43 Neutral
• Price Target: ―

SciBase Holding AB demonstrates strengths in revenue growth and a debt-free balance sheet, reducing financial risk. However, significant challenges remain with profitability and cash flow, reflected in the negative P/E ratio and lack of dividends. The technical indicators show a lack of momentum, suggesting cautious investor sentiment. Strategic improvements are needed to enhance profitability and operational efficiency.

SciBase Holding AB Business Overview & Revenue Model

Company Description

SciBase Holding AB (publ), a medical technology company, develops and sells instruments for the detection of skin cancer and other skin conditions in Europe and internationally. Its product includes Nevisense and Nevisense Go, a point of care platform that addresses in the areas of melanoma detection, non-melanoma skin cancer detection, and skin barrier assessment. The company has a collaboration agreement with Advanced Dermatology and Cosmetic Surgery (ADCS) group. SciBase Holding AB (publ) was founded in 1998 and is headquartered in Sundbyberg, Sweden.

How the Company Makes Money

SciBase Holding AB generates revenue primarily through the sale of its Nevisense devices and related consumables to dermatology clinics, hospitals, and healthcare providers. The company also earns income from providing training and support services associated with the use of its products. Additionally, SciBase may engage in strategic partnerships or collaborations with research institutions or other medical technology companies to expand the reach and application of its diagnostic solutions. Revenue growth is influenced by factors such as regulatory approvals, market adoption, and the company's ongoing investment in research and development to enhance its product offerings.

SciBase Holding AB Financial Statement Overview

Summary

SciBase Holding AB shows promising revenue growth and a solid equity base with no long-term debt, which reduces financial risk. However, profitability challenges persist with negative net profit margins and ongoing cash burn, necessitating strategic improvements for operational efficiency.

Income Statement

SciBase Holding AB has shown consistent revenue growth over the years, with a notable improvement from SEK 9.52M in 2020 to SEK 29.71M in 2024. Despite this positive trend, the company struggles with profitability, evidenced by negative net profit margins and EBIT margins over the years. The gross profit margin remains relatively strong, suggesting effective cost management at the gross level. However, the persistent operating losses and negative EBITDA highlight ongoing challenges in achieving operational efficiency.

Balance Sheet

The balance sheet indicates a stable equity position with no long-term debt in 2024, which reduces financial risk. The equity ratio is strong, reflecting a solid proportion of funding from shareholders. However, the return on equity is negative due to ongoing net losses, which is a concern for investors. The declining asset base over recent years may indicate potential challenges in asset management or investment.

Cash Flow

Cash flow analysis reveals consistent negative free cash flow, indicating cash burn that is not yet offset by operational activities. The operating cash flow to net income ratio shows a close alignment, suggesting that accounting adjustments are not significantly distorting cash performance. The company has been reliant on financing activities to fund operations, as evidenced by substantial cash inflows from financing in 2024.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	29.70M	23.25M	17.89M	11.73M	9.52M
Gross Profit	21.08M	16.04M	11.23M	6.58M	5.00M
EBITDA	-57.59M	-51.83M	-39.33M	-38.58M	-32.19M
Net Income	-61.13M	-55.59M	-39.90M	-41.69M	-34.99M
Balance Sheet
Total Assets	61.73M	64.33M	49.85M	85.46M	59.25M
Cash, Cash Equivalents and Short-Term Investments	11.24M	34.12M	18.83M	65.61M	41.43M
Total Debt	0.00	6.80M	8.12M	2.86M	1.92M
Total Liabilities	25.08M	21.28M	24.62M	14.66M	12.39M
Stockholders Equity	36.65M	43.06M	25.24M	70.80M	46.86M
Cash Flow
Free Cash Flow	-57.81M	-52.37M	-44.85M	-40.12M	-34.16M
Operating Cash Flow	-57.38M	-51.98M	-44.47M	-39.50M	-33.86M
Investing Cash Flow	-428.00K	-383.00K	-381.00K	-526.00K	858.00K
Financing Cash Flow	34.91M	67.68M	-2.48M	64.22M	47.90M

SciBase Holding AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.38
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SCIB, the sentiment is Negative. The current price of 0.38 is above the 20-day moving average (MA) of 0.38, below the 50-day MA of 0.39, and below the 200-day MA of 0.41, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.12 is Neutral, neither overbought nor oversold. The STOCH value of 11.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SCIB.

SciBase Holding AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.53B	0.32	-61.76%	2.28%	16.60%	1.56%
ACARIX	46 Neutral	kr361.14M	―	-88.97%	―	-0.61%	54.19%
QLINEA	43 Neutral	kr412.14M	―	-159.24%	―	-22.50%	76.74%
QLINEA	43 Neutral	kr412.14M	―	-159.24%	―	-22.50%	76.74%
SPEC	43 Neutral	€105.75M	―	-20.45%	―	―	-10.85%
SPEC	43 Neutral	€105.75M	―	-20.45%	―	―	-10.85%
SCIB	43 Neutral	kr126.86M	―	-209.61%	―	27.78%	43.32%
HEART	34 Underperform	kr68.48M	―		―	―	―
QLIFE	33 Underperform	kr62.17M	―		―	-63.52%	93.00%